- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Kiniksa Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $27.59 – an increase of 2.99% over the previous week. Kiniksa Pharmaceuticals employs 297 staff and has a trailing 12-month revenue of around $338.9 million.
What's in this guide?
Our top picks for where to buy Kiniksa Pharmaceuticals stock
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Kiniksa Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – KNSA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Kiniksa Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Kiniksa Pharmaceuticals stock price (NASDAQ: KNSA)
Use our graph to track the performance of KNSA stocks over time.Kiniksa Pharmaceuticals shares at a glance
Information last updated 2024-10-24.
| Latest market close | $27.59 |
|---|---|
| 52-week range | $14.12 - $27.92 |
| 50-day moving average | $25.64 |
| 200-day moving average | $21.40 |
| Wall St. target price | $34.20 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.15 |
Is it a good time to buy Kiniksa Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Kiniksa Pharmaceuticals price performance over time
Historical closes compared with the close of $27.44 from 2024-10-25
| 1 week (2024-10-22) | 2.43% |
|---|---|
| 1 month (2024-09-27) | 9.76% |
| 3 months (2024-07-29) | 4.97% |
| 6 months (2024-04-29) | 47.92% |
| 1 year (2023-10-27) | 79.93% |
|---|---|
| 2 years (2022-10-28) | 134.13% |
| 3 years (2021-10-29) | 164.10% |
| 5 years (2019-10-29) | 295.96% |
Kiniksa Pharmaceuticals financials
| Revenue TTM | $338.9 million |
|---|---|
| Gross profit TTM | $173.2 million |
| Return on assets TTM | -3.35% |
| Return on equity TTM | -2.42% |
| Profit margin | -3.02% |
| Book value | $6.12 |
| Market Capitalization | $1.9 billion |
TTM: trailing 12 months
Kiniksa Pharmaceuticals share dividends
We're not expecting Kiniksa Pharmaceuticals to pay a dividend over the next 12 months.
Have Kiniksa Pharmaceuticals's shares ever split?
Kiniksa Pharmaceuticals's shares were split on 27 June 2024 .
Kiniksa Pharmaceuticals share price volatility
Over the last 12 months, Kiniksa Pharmaceuticals's shares have ranged in value from as little as $14.12 up to $27.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiniksa Pharmaceuticals's is 0.32. This would suggest that Kiniksa Pharmaceuticals's shares are less volatile than average (for this exchange).
Kiniksa Pharmaceuticals overview
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom. .
Frequently asked questions
What percentage of Kiniksa Pharmaceuticals is owned by insiders or institutions?Currently 4.249% of Kiniksa Pharmaceuticals shares are held by insiders and 89.96% by institutions. How many people work for Kiniksa Pharmaceuticals?
Latest data suggests 297 work at Kiniksa Pharmaceuticals. When does the fiscal year end for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals's fiscal year ends in December. Where is Kiniksa Pharmaceuticals based?
Kiniksa Pharmaceuticals's address is: 23 Old Bond Street, London, United Kingdom, WIS 4PZ What is Kiniksa Pharmaceuticals's ISIN number?
Kiniksa Pharmaceuticals's international securities identification number is: BMG5269C1010 What is Kiniksa Pharmaceuticals's CUSIP number?
Kiniksa Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: G5269C101
More resources on Finder
More guides on Finder
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
SoFi Invest® review 2024: Simple investing, free CFP access
SoFi Invest is a commission-free platform with both active and automated investment accounts.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
Robinhood Review 2024: IRA Match and No Commissions
A deep dive into the highlights and limitations of Robinhood.
Ask a question